• 1
    Royston D, Bidstrup BP, Taylor KM, Sapsford RN. Effect of aprotinin on need for blood transfusion after repeat open-heart surgery. Lancet. 1987; 2: 1289-1291.
  • 2
    Bidstrup BP, Royston D, Sapsford RN, Taylor KM. Reduction in blood loss and blood use after cardiopulmonary bypass with high dose aprotinin (Trasylol). J Thorac Cardiovasc Surg. 1989; 97: 364-372.
  • 3
    Murkin JM, Lux J, Shannon NA, et al. Aprotinin significantly decreases bleeding and transfusion requirements in patients receiving aspirin and undergoing cardiac operations. J Thorac Cardiovasc Surg. 1994; 107: 554-561.
  • 4
    Mangano DT, Tudor IC, Dietzel C. The risk associated with aprotinin in cardiac surgery. N Engl J Med. 2006; 354: 353-365.
  • 5
    Lentschener C, Benhamou D, Mercier FJ, et al. Aprotinin reduces blood loss in patients undergoing elective liver resection. Anesth Analg. 1997; 84: 875-881.
  • 6
    Capdevila X, Calvet Y, Biboulet P, Biron C, Rubenovitch J, d'Athis F. Aprotinin decreases blood loss and homologous transfusions in patients undergoing major orthopedic surgery. Anesthesiology. 1998; 88: 50-57.
  • 7
    Poullis M, Manning R, Laffan M, Haskard DO, Taylor KM, Landis RC. The antithrombotic effect of aprotinin: actions mediated via the protease-activated receptor I. J Thorac Cardiovasc Surg. 2000; 120: 370-378.
  • 8
    Treasure T, Sedrakyan A. Pleural mesothelioma: little evidence, still time to do trials. Lancet. 2004; 364: 1183-1185.
  • 9
    Zacharski L. Anticoagulants in cancer treatment: malignancy as a solid phase coagulopathy. Cancer Lett. 2002; 186: 1.
  • 10
    O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics. 1979; 35: 549-556.
  • 11
    Kaplan EL, Meier P. Nonparametric estimator from incomplete observations. J Am Stat Assoc. 1958; 53: 457-481.
  • 12
    Mantel N. Evaluation of survival data and 2 new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966; 60: 163-170.
  • 13
    Randles RH, Wolfe DA. Introduction to the Theory of Nonparametric Statistics. New York: John Wiley & Sons; 1979.
  • 14
    Therneau TM, Grambsch.PA. Modeling Survival Data. New York: Springer; 2000.
  • 15
    Ibrahim JG, Chen M-H, Sinha D. Bayesian Survival Analysis. New York: Springer; 2001.
  • 16
    Venables WN, Ripley BD. Modern Applied Statistics With S. 4th ed. New York: Springer; 2002.
  • 17
    Imperial College and Medical Research Council. WinBugs Version 1.4. London, UK: Imperial College and Medical Research Council; 2003.
  • 18
    US Food and Drug Administration. FDA revises labeling for Trasylol (aprotinin injection) to strengthen safety warnings and limit usage of drug to specific situations [press release]. FDA News. 2006; P06-P203.
  • 19
    Bakaaen F, Rice D, Correa AM, et al. Use of aprotinin in extrapleural pneumonectomy: effect on hemostasis and incidence of complications. Ann Thorac Surg. 2007; 84: 986-987.
  • 20
    Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003; 21: 2636-2644.
  • 21
    Latner AL, Longstaff E, Pradhan K. Inhibition of malignant cell invasion in vitro by a proteinase inhibitor. Br J Cancer. 1973; 27: 460-464.
  • 22
    Latner AL, Longstaff E. Antitumor activity of aprotinin. Br J Cancer. 1974; 30: 60-67.
  • 23
    Vaporciyan AA, Putnam JB, Smythe WR. The potential role of aprotinin in the perioperative management of malignant tumors. J Am Coll Surg. 2004; 198: 266-278.
  • 24
    Mikhalkin IA, Iashvili ZG, Bykov VL. Thermoradiotherapy combined with a proteolysis inhibitor (Contrical) in the treatment of head and neck cancer. Oncology. 1993; 50: 344-347.
  • 25
    Lentschener C, Li H, Franco D, et al. Intraoperatively administered aprotinin and survival after elective liver resection for colorectal cancer metastases. A preliminary study. Fibrinolys Proteolys. 1999; 13: 39-45.
  • 26
    Zimbler N, Wall CN, Townsend ER, Royston D. Use of intra-operative high dose aprotinin may be associated with improved longer term outcome following esophagectomy for cancer [Abstract A1187]. Presented at the Annual Meeting of the American Society of Anesthesiologists, Orlando, Florida, October 12-16, 2002.
  • 27
    Hayashi I, Amano H, Yoshida S, et al. Suppressed angiogenesis in kininogen-deficiencies. Lab Invest. 2002; 82: 871-880.
  • 28
    Ploplis VA, Tipton H, Menchen H, Castellino FJ. A urokinase-type plasminogen activator deficiency diminishes the frequency of intestinal adenomas in Apc(Min/+) mice. J Pathol. 2007; 213: 266-274.
  • 29
    Uchima Y, Sawada T, Hirakawa K. Action of antiproteases on pancreatic cancer cells. JOP. 2007; 8( 4 suppl): 479-487.
  • 30
    Perkins RC, Broaddus VC, Shetty S, Hamilton S, Idell S. Asbestos up-regulates expression of the urokinase-type plasminogen activator receptor on mesothelial cells. Am J Respir Cell Mol Biol. 1999; 21: 637-646.
  • 31
    Heidtmann HH, Hofmann M, Jacob E, Erbil C, Havemann K, Schwartz-Albiez R. Synthesis and secretion of plasminogen activators and plasminogen activator inhibitors in cell lines of different groups of human lung tumors. Cancer Res. 1989; 49(24 pt 1): 6960-6965.
  • 32
    Treasure T, Tan C, Lang-Lazdunski L, Waller D. The MARS trial: mesothelioma and radical surgery. Interact Cardiovasc Thorac Surg. 2006; 5: 58-59.
  • 33
    Ferguson TB. Aprotinin-are there lessons learned [editorial]? JAMA. 2007; 297: 527-529.